非肌层浸润性膀胱癌患者在经尿道膀胱肿瘤电切术前即刻接受新辅助膀胱内丝裂霉素-C治疗的临床疗效:一项前瞻性随机II期研究的初步结果
这项单中心、开放标签、平行组、随机II期试验在疑似非肌层浸润性膀胱癌患者中比较了经尿道膀胱肿瘤电切术前接受2剂膀胱内丝裂霉素-C(40 mg/20 mL,术前1天及4小时前给药)与不治疗的疗效与安全性。结果显示干预组1年无复发生存率为97%,对照组为89%;干预组复发风险相对降低63%(HR 0.37;80%单侧CI -∞-0.65,P=0.11)。作者认为两剂新辅助膀胱内丝裂霉素-C安全且有效减少复发和进展。
要点
- 术前1天及4小时前给予2剂膀胱内丝裂霉素-C(40 mg/20 mL)安全,不良事件为局部1/2级。
- 干预组1年无复发生存率97%,对照组89%;复发风险相对降低63%(HR 0.37;80%单侧CI -∞-0.65,P=0.11)。
- 对照组3例发生疾病进展,干预组无进展(P=0.051)。
核心结论
- 两剂新辅助膀胱内丝裂霉素-C在经尿道膀胱肿瘤电切术后减少非肌层浸润性膀胱癌复发和进展方面安全且有效。
研究设计与样本
- 单中心、开放标签、平行组、随机II期临床试验,纳入疑似非肌层浸润性膀胱癌且拟行经尿道膀胱肿瘤电切术的患者。
- 按1:1随机分为干预组(n=49)和对照组(n=50),采用区组随机化(区组大小2和4),按卡介苗/膀胱内丝裂霉素-C分层。
- 干预组在经尿道膀胱肿瘤电切术前1天及4小时前接受2剂膀胱内丝裂霉素-C(40 mg/20 mL),对照组不接受治疗。
- 主要终点为无复发生存期,次要终点为无进展生存期和不良事件,采用符合方案集分析。
- 符合方案集共71例(干预组33例,对照组38例),基线特征匹配良好;61例无复发随访至少10.4个月。
主要发现
- 干预组3例、对照组8例出现复发。
- 1年无复发生存率干预组为97%,对照组为89%。
- 新辅助膀胱内丝裂霉素-C使相对复发风险降低63%(风险比0.37;80%单侧置信区间 -∞-0.65,P=0.11)。
- 对照组3例发生疾病进展,干预组无进展(P=0.051)。
- 新辅助膀胱内丝裂霉素-C耐受良好,不良事件为局部且为1/2级。
临床怎么用
- 原文结论认为两剂新辅助膀胱内丝裂霉素-C安全且有效减少非肌层浸润性膀胱癌复发和进展,未给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intravesical mitomycin-C is recommended immediately after transurethral resection of bladder tumor for nonmuscle-invasive bladder cancer. However, a lack of compliance occurs due to the associated complications. Here, we aimed to assess the efficacy and safety of intravesical mitomycin-C before transurethral resection of bladder tumor in patients with nonmuscle-invasive bladder cancer. MATERIALS AND METHODS: This was a single-center, open-label, parallel-arm, randomized phase II clinical trial in patients with suspected nonmuscle-invasive bladder cancer before transurethral resection of bladder tumor. Participants were randomly assigned (1:1) to receive 2 doses of intravesical mitomycin-C (40 mg/20 mL) 1 day and 4 hours before transurethral resection of bladder tumor (n = 49) or no treatment (n = 50) with block randomization (size 2 and 4), stratified by bacillus Calmette-Guérin/intravesical mitomycin-C. The primary endpoint was recurrence-free survival and secondary endpoints were progression-free survival and adverse events in the per-protocol analysis. RESULTS: Seventy-one patients (33, intervention; 38, control) were well matched for baseline characteristics. Sixty-one had been followed without recurrence for at least 10.4 months; 3 and 8 patients showed recurrence in the intervention and control groups, respectively. The 1-year recurrence-free survival rate was 97% and 89% for the intervention and control groups, respectively. Neoadjuvant intravesical mitomycin-C resulted in a reduction (63%) in the relative recurrence risk (hazard ratio, 0.37; 80% 1-sided confidence interval, -∞-0.65, P = .11). Disease progression occurred in 3 patients in the control group (P = .051) but not in the intervention group. Neoadjuvant intravesical mitomycin-C was well tolerated, and adverse events were local and of grade 1/2. CONCLUSIONS: Two doses of neoadjuvant intravesical mitomycin-C are safe and effective in reducing nonmuscle-invasive bladder cancer recurrence and progression after transurethral resection of bladder tumor.
引用
- Lee HW, Lee HH, Park EY, et al. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. J Urol. 2022. PMID: 36250938. doi:10.1097/JU.0000000000003002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。